ANNX (Annexon) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANNX Annexon Inc ANNX
34 GF Score
Price $4.21
! 2 Warning Signs
View Full Analysis

What is Annexon Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Annexon Valuation Rank Related Terms

ANNX
34GF Score
Annexon Inc ANNX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexon Business Description

Address 1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc. is a clinical-stage biopharmaceutical company based in the United States that develops therapies targeting the classical complement pathway, a part of the immune system implicated in autoimmune and neurodegenerative diseases. Its pipeline is built on a platform designed to block C1q and the entire classical complement cascade. The company's lead candidates include ANX005, an intravenous antibody for autoimmune and neurodegenerative disorders such as Guillain-Barré syndrome and Huntington's disease; ANX007, an antibody fragment for neurodegenerative ophthalmic conditions including geographic atrophy; ANX009, for systemic autoimmune diseases; and ANX1502, an oral small-molecule candidate. As a clinical-stage company, Annexon does not yet generate product revenue and funds its operations primarily through equity financings, collaboration arrangements, and licensing. Its activities are centered on research, clinical development, and regulatory interactions in the United States and other markets.
34GF Score

Get the complete analysis for ANNX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.21
Price